N-(tert-butoxycarbonyl) aspartic acid-1-phenylbutyl amide | 1377152-21-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-(tert-butoxycarbonyl) aspartic acid-1-phenylbutyl amide
• 英文别名: N-(tert-butoxycarbonyl)aspartic acid-1-phenyl butylamide；(3S)-3-[(2-methylpropan-2-yl)oxycarbonylamino]-4-oxo-4-(1-phenylbutylamino)butanoic acid
• CAS: 1377152-21-0
• 化学式: C₁₉H₂₈N₂O₅
• 分子量: 364.442
• InChiKey: WROJYJYMAGRAAF-LOACHALJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  26
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  105
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-(tert-butoxycarbonyl) aspartic acid-1-phenylbutyl amide 在 盐酸 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 生成 aspartic acid-1-phenylbutyl amide-4-(3'-ethynylcytidine) amide
  参考文献：
  名称：

  POLYMER DERIVATIVE OF CYTIDINE METABOLISM ANTAGONIST

  摘要：

  公开号：

  EP2641605B1
• 作为产物：
  描述：

  Boc-L-天冬氨酸 4-苄酯 在 5%-palladium/activated carbon 、 氢气 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 N-(tert-butoxycarbonyl) aspartic acid-1-phenylbutyl amide
  参考文献：
  名称：

  POLYMER DERIVATIVE OF CYTIDINE METABOLISM ANTAGONIST

  摘要：

  公开号：

  EP2641605B1

文献信息

• Polymeric Compound Having Camptothecin Compound And Anti-Cancer Effect Enhancer Bound Thereto, And Use of Same
  申请人：NIPPON KAYAKU KABUSHIKI KAISHA

  公开号：US20150290185A1

  公开（公告）日：2015-10-15

  The purpose of the present invention is to provide a polymeric compound in which a camptothecin compound and an anti-cancer effect enhancer, particularly a PARP inhibitor, are bound to a single molecule, whereby it becomes possible to reduce the toxicity to normal cells and deliver and release the two components to an affected area with high efficiency to thereby improve the pharmacological efficacy of the two components. Provided is a polymeric compound represented by general formula (1).

  本发明的目的是提供一种聚合物化合物，其中一种喜树碱化合物和一种抗癌效应增强剂，特别是PARP抑制剂，结合到单个分子中，从而可以降低对正常细胞的毒性，并以高效率将两个组分传递和释放到受影响的区域，从而提高两个组分的药理功效。提供了由通式（1）表示的聚合物化合物。
• Novel Polymer Derivative Of Cytidine Metabolic Antagonist
  申请人：Yamamoto Keiichirou

  公开号：US20130331517A1

  公开（公告）日：2013-12-12

  [Problem] To provide a novel polymer derivative of a cytidine metabolic antagonist which allows release of a medicament irrespective of enzymes of the living body and is expected to have high therapeutic effects. [Solution] The polymer derivative of a cytidine metabolic antagonist in which a substituent represented by the general formula (I) or the general formula (II) [wherein R 7 and R 8 each independently represent a hydrogen atom or an optionally substituted (C1-C6)alkyl group, R 6 represents a hydrogen atom, an optionally substituted (C1-C40)alkyl group, an optionally substituted (C1-C40)aralkyl group, an optionally substituted aromatic group, an amino acid residue in which the carboxy group is protected, or an optionally substituted sugar residue, CX—CY represents CH—CH or C═C (double bond), and A represents the residue of the cytidine metabolic antagonist except the amino group at the position 4] is bonded to the side-chain carboxy group of a block copolymer of a polyethylene-glycol structural moiety and a polymer having 10 or more carboxy groups.

  [问题] 提供一种新型的胞苷代谢拮抗剂的聚合物衍生物，该衍生物允许药物的释放不受生物体内酶的影响，并有望具有高疗效。 [解决方案] 通过将由一般式（I）或一般式（II）表示的取代基（其中R7和R8各自独立地表示氢原子或可选取代的（C1-C6）烷基，R6表示氢原子，可选取代的（C1-C40）烷基，可选取代的（C1-C40）芳基烷基，可选取代的芳香基，带有保护羧基的氨基酸残基或可选取代的糖残基，CX - CY表示CH-CH或C = C（双键），A表示除位置4的氨基以外的胞苷代谢拮抗剂的残基）连接到具有10个或更多羧基的聚乙二醇结构单元和聚合物的侧链羧基上，得到一种胞苷代谢拮抗剂的聚合物衍生物。
• Polymer derivative of cytidine metabolic antagonist
  申请人：Yamamoto Keiichirou

  公开号：US09018323B2

  公开（公告）日：2015-04-28

  [Problem]To provide a novel polymer derivative of a cytidine metabolic antagonist which allows release of a medicament irrespective of enzymes of the living body and is expected to have high therapeutic effects. [Solution] The polymer derivative of a cytidine metabolic antagonist in which a substituent represented by the general formula (I) or the general formula (II) [wherein R7 and R8 each independently represent a hydrogen atom or an optionally substituted (C1-C6)alkyl group, R6 represents a hydrogen atom, an optionally substituted (C1-C40)alkyl group, an optionally substituted (C1-C40)aralkyl group, an optionally substituted aromatic group, an amino acid residue in which the carboxy group is protected, or an optionally substituted sugar residue, CX—CY represents CH—CH or C═C (double bond), and A represents the residue of the cytidine metabolic antagonist except the amino group at the position 4] is bonded to the side-chain carboxy group of a block copolymer of a polyethylene-glycol structural moiety and a polymer having 10 or more carboxy groups.

  [问题] 提供一种新型的胞苷代谢拮抗剂的聚合物衍生物，该聚合物衍生物可以无视生物体内的酶释放药物，并且预计具有高疗效。 [解决方案] 一种胞苷代谢拮抗剂的聚合物衍生物，其中置换基由通式（I）或通式（II）表示[其中R7和R8各自独立地表示氢原子或可选取代的（C1-C6）烷基，R6表示氢原子、可选取代的（C1-C40）烷基、可选取代的（C1-C40）芳基烷基、可选取代的芳香基、羧基保护的氨基酸残基或可选取代的糖残基，CX-CY表示CH-CH或C═C（双键），A表示除位置4上的氨基外的胞苷代谢拮抗剂残基]与具有10个或更多羧基的聚乙二醇结构基团和聚合物的侧链羧基结合。
• NOVEL POLYMER DERIVATIVE OF CYTIDINE METABOLISM ANTAGONIST
  申请人：Nippon Kayaku Kabushiki Kaisha

  公开号：EP2641605A1

  公开（公告）日：2013-09-25

  [Problem] To provide a novel polymer derivative of a cytidine metabolic antagonist which allows release of a medicament irrespective of enzymes of the living body and is expected to have high therapeutic effects. [Solution] The polymer derivative of a cytidine metabolic antagonist in which a substituent represented by the general formula (I) or the general formula (II) [wherein R7 and R8 each independently represent a hydrogen atom or an optionally substituted (C1-C6)alkyl group, R6 represents a hydrogen atom, an optionally substituted (C1-C40)alkyl group, an optionally substituted (C1-C40)aralkyl group, an optionally substituted aromatic group, an amino acid residue in which the carboxy group is protected, or an optionally substituted sugar residue, CX-CY represents CH-CH or C=C (double bond), and A represents the residue of the cytidine metabolic antagonist except the amino group at the position 4] is bonded to the side-chain carboxy group of a block copolymer of a polyethylene-glycol structural moiety and a polymer having 10 or more carboxy groups.

  问题 提供一种新型胞苷代谢拮抗剂聚合物衍生物，该衍生物可释放药物而不受活体酶的影响，并有望产生较高的治疗效果。 [解决方案］ 胞苷代谢拮抗剂的聚合物衍生物，其中由通式(I)或通式(II)代表的取代基[其中R7和R8各自独立地代表氢原子或任选取代的(C1-C6)烷基，R6代表氢原子、任选取代的(C1-C40)烷基、任选取代的(C1-C40)芳基、任选取代的芳基、CX-CY代表CH-CH或C=C（双键），A代表胞苷代谢拮抗剂的残基，但第4位的氨基除外]与聚乙二醇结构分子的嵌段共聚物和具有10个或更多羧基的聚合物的侧链羧基键合。
• POLYMERIC COMPOUND HAVING CAMPTOTHECIN COMPOUND AND ANTI-CANCER EFFECT ENHANCER BOUND THERETO, AND USE OF SAME
  申请人：Nippon Kayaku Kabushiki Kaisha

  公开号：EP2918292A1

  公开（公告）日：2015-09-16

  The purpose of the present invention is to provide a polymeric compound in which a camptothecin compound and an anti-cancer effect enhancer, particularly a PARP inhibitor, are bound to a single molecule, whereby it becomes possible to reduce the toxicity to normal cells and deliver and release the two components to an affected area with high efficiency to thereby improve the pharmacological efficacy of the two components. Provided is a polymeric compound represented by general formula (1).

  本发明的目的是提供一种高分子化合物，其中喜树碱化合物和抗癌效果增强剂，特别是 PARP 抑制剂被结合到单个分子中，从而可以降低对正常细胞的毒性，并将这两种成分高效地输送和释放到受影响的区域，从而提高这两种成分的药效。本发明提供了一种由通式（1）表示的聚合物化合物。